Berlin Cures Completes Screening Phase of BC 007 Trial in Fight Against Long COVID

Berlin, Germany, 23 April 2024 – Berlin Cures Holding AG, a biotechnology pioneer, today disclosed the successful wrap-up of the patient screening phase for its BC 007 Phase II pan-European trial, aimed at combating Long COVID. This marks a key advancement, with the trial set to move swiftly into subsequent stages, expecting preliminary results by autumn 2024.

The trial boasts 114 participants across various centers in Finland, Germany, Austria, Switzerland, and Spain. With the screening phase concluded, the study will not accept more participants as it prepares for forthcoming phases of the clinical trial.

Oliver von Stein, CEO of Berlin Cures, noted this rapid recruitment reflects the urgent demand for effective Long COVID treatments and underscores the company’s commitment to rigorous scientific research aimed at enhancing patient outcomes. The BC 007 drug specifically targets pathogenic functional autoantibodies thought to contribute to Long COVID symptoms.

The completion of this phase paves the way for the crucial Phase III trial, essential for regulatory approval and eventual market release of BC 007. Berlin Cures is currently seeking financial partners to push forward the commencement of the Phase III trial.